Scott L. Burrows - Jan 15, 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Jan 15, 2025
Transactions value $
$0
Form type
4
Date filed
1/17/2025, 04:36 PM
Previous filing
Sep 5, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +95.5K $0.00 95.5K Jan 15, 2025 Common Stock 95.5K $21.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.